Vaccinex shares are trading higher after the company announced its next generation ActivMAb technology was published in mAbs and validated in an OmniAb proof-of-concept collaboration.
Portfolio Pulse from Benzinga Newsdesk
Vaccinex shares are trading higher following the publication of its next generation ActivMAb technology in mAbs and its validation in an OmniAb proof-of-concept collaboration.
September 28, 2023 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaccinex's stock is trading higher due to the publication and validation of its ActivMAb technology.
The publication and validation of Vaccinex's ActivMAb technology is a positive development for the company. This could potentially lead to increased investor confidence and demand for the stock, driving its price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100